HAEM5:Classic Hodgkin lymphoma: Difference between revisions

[pending revision]

@@ Line 96: / Line 96: @@
 |9p24.1 amplification drives PD-L1/PD-L2 overexpression, relevant for immune checkpoint inhibitor therapy (PMID: 20628145, 27069084)
 |-
-|<span class="blue-text">EXAMPLE:</span>
+|17p
+|Gain
-|<span class="blue-text">EXAMPLE:</span> Amp
+|17q21
-|<span class="blue-text">EXAMPLE:</span>
+|MAP3K14
-q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
+|P
-|<span class="blue-text">EXAMPLE:</span>
+|No
-''ERBB2''
+|MAP3K14 (NIK) gain activates alternative NF-κB signaling (PMID: 19380639)
-|<span class="blue-text">EXAMPLE:</span> D, P, T
-|
-|<span class="blue-text">EXAMPLE:</span>
-Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
 |-
-|
+|6q
-|
+|Loss
-|
+|6q23-24
-|
+|TNFAIP3
-|
+|P
-|
+|No
-|
+|Loss of TNFAIP3 (A20) disrupts NF-κB regulation (PMID: 19380639)
 |}